Patents Examined by Thaian N. Ton
  • Patent number: 10443044
    Abstract: This disclosure provides a chemically modified induced pluripotent stem (iPS) cell derived from parental cells and methods for generating the chemically induced pluripotent stem (iPS) cells, as well as cardiac progenitor cells capable of producing cells of multiple sub-lineages. The iPS cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue or to rejuvenating cardiac muscles in a patient in need thereof and to treat cardiac disease.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 15, 2019
    Assignee: IPS Heart
    Inventor: Muhammad Ashraf
  • Patent number: 10443042
    Abstract: Disclosed herein are methods for generating SC-? cells using chemically defined, completely serum free media, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 15, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Douglas A. Melton, Mads G├╝rtler
  • Patent number: 10443071
    Abstract: Methods of producing hepatocyte lineage cells are provided. The method can include transfecting a cell with one or more expression vectors. For example, a cell can be transfected with a first expression vector containing a first gene that encodes CCAAT/enhancer binding protein alpha (CEBPA), a second expression vector containing a second gene that encodes CCAAT/enhancer binding protein beta (CEBPB), a third expression vector containing a third gene that encodes forkhead box A1 (FOXA1), and a fourth expression vector containing a fourth gene that encodes forkhead box A3 (FOXA3). The method can include culturing the transfected cell obtained in a growth environment. The transfected cell can be cultured in Williams' E medium, ReproFF (feeder-free media maintaining pluripotency) medium, or both. Transfected and/or hepatocyte lineage cells obtained by a method of the present invention are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: October 15, 2019
    Assignee: National University Corporation Chiba University
    Inventor: Minoru Tomizawa
  • Patent number: 10435710
    Abstract: Aspects of the present disclosure are directed to methods and compositions for the production of heterogeneous tissue from human induced pluripotent stem (hiPS) cells.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 8, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Patrick Guye, Ron Weiss, Mohammad Reza Ebrahimkhani
  • Patent number: 10435711
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 8, 2019
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 10435666
    Abstract: The first method to cause a culture of human and other primate stem cells to directly and uniformly differentiate into a committed cell lineage is disclosed. Treatment of primate stem cells with a single protein trophoblast induction factor causes the cells to transform into human trophoblast cells, the precursor cells of the placenta. Several protein factors including bone morphogenic protein 4 (BMP4), BMP2, BMP7, and growth and differentiation factor 5 can serve as trophoblast-inducting factors.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: October 8, 2019
    Assignee: WiCell Research Institute, Inc.
    Inventors: Ren-He Xu, James A. Thomson
  • Patent number: 10428310
    Abstract: Methods and compositions are provided for generating or maintaining human iPS cells in culture. Methods include the use of a low osmolality medium to make human iPS cells, or use of a low osmolality medium to maintain human iPS cells. Methods for making targeted genetic modification to human iPS cells cultured in low osmolality medium are also included. Compositions include human iPS cells cultured and maintained using the low osmolality medium defined herein.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: October 1, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Junko Kuno, Wojtek Auerbach, David M. Valenzuela
  • Patent number: 10426147
    Abstract: Provided is a gene expression system, suitable for expression in an insect, comprising an insect muscle actin promoter operably linked to a marker gene, which overcomes or ameliorates one or more of: cost of rearing; amount of handling; errors in identification due to human error or loss of marker by the insect; and health concerns related to the effects of marker powders on workers in mass rearing facilities.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 1, 2019
    Assignee: Oxitec Limited
    Inventors: Martha Koukidou, Sarah Scaife, Luke Alphey
  • Patent number: 10426799
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: December 21, 2013
    Date of Patent: October 1, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 10428307
    Abstract: The present invention relates to a method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors and, more specifically, a method for converting mesenchymal stem cells into endothelial cells by using Oct4, Nanog, Tal1, and LMO2, which are specific transcription factors. According to the present invention, the method for converting adult cells or mesenchymal stem cells, which are adult stem cells, into endothelial cells was developed by selecting two types of genes, which are less directly related to cancer induction, among cell reprogramming factors and two types of transcription factors, which are not expressed or expressed at a low level in mesenchymal stem cells, among transcription factors related to vascular development, and combining all four transcription factors. The method can be applied in the production of endothelial cells for forming regenerative tissue in tissue engineering and ischemic disease therapy.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 1, 2019
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventor: Young-Ae Joe
  • Patent number: 10413571
    Abstract: Isolated or purified mammalian kidney-derived cell populations from mammalian kidney tissue are provided. Methods are provided for the isolation and purification of the mammalian kidney-derived cell population. Methods for treating kidney disease are provided by administration of the isolated or purified mammalian kidney-derived cell population to a mammalian subject.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: September 17, 2019
    Assignee: DePuy Synthes Products, Inc.
    Inventors: David C. Colter, Agnieszka Seyda, Charito S. Buensuceso, Anna Gosiewska
  • Patent number: 10412939
    Abstract: This disclosure provides a rodent model of prostate cancer. The rodents disclosed herein comprise a transgene that provides prostate-specific expression of an oncogenic protein (e.g, an SV40 tumor antigen) under the control of 5? and 3? regulatory regions of a mouse probasin gene. The rodents develop progressive forms of prostate tumor that resemble the development of human prostate cancer.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 17, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Chia-Jen Siao, Hoi-Ching Lee, Zhe Li, Ka-Man Venus Lai, Gavin Thurston
  • Patent number: 10407665
    Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: September 10, 2019
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
  • Patent number: 10408813
    Abstract: Cyclic adenosine monophosphate (cAMP) biosensors comprising a Renilla luciferase (RLuc), a green fluorescent protein (GFP), and an exchange protein activated by cAMP, and uses thereof in determining cAMP levels both in vivo and in vitro. Another aspect of the invention relates to methods for controlling blood glucose levels.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 10, 2019
    Assignee: Academia Sinica
    Inventors: Klim King, Yu-Heng Cheng
  • Patent number: 10391156
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: August 27, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 10385359
    Abstract: Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: August 20, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeffrey D. Lee, Alexander O. Mujica, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Patent number: 10370645
    Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 6, 2019
    Assignees: Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hopsital, Inc., President and Fellows of Harvard College
    Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
  • Patent number: 10370638
    Abstract: The present invention provides a technique that serves as a platform for inducing human organ cells at a low cost, stably and in a large quantity. A cell inducible after differentiating pluripotent stem cells and then passaging the resultant cells at least once or more times, which is negative for undifferentiated (pluripotent) cell markers NANOG, OCT4, MYC and LIN28A, negative for endoderm cell markers CXCR4, CER1, HHEX and GATA4, positive for intestinal endoderm cell markers CDX2 and HOXB9, negative for a mesenchymal cell marker brachyury (T), negative for a pancreatic cell marker PDX1, and capable of differentiating into at least a hepatocyte, a pancreatic cell and an intestinal cell. Also provided are methods of preparing and amplifying the above cells; a method of preparing organ cells using the above cells; and a method of constructing a working cell bank for preparing organ cells, comprising cryopreserving the above cells.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: August 6, 2019
    Assignee: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
    Inventors: Takanori Takebe, Hideki Taniguchi, Ran ran Zhang
  • Patent number: 10370646
    Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and use thereof.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: August 6, 2019
    Assignee: The Regents of the University of California
    Inventors: Steven F. Dowdy, Naohisa Yoshioka
  • Patent number: 10358628
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: July 23, 2019
    Assignee: JANSSEN BIOTECH, INC.
    Inventor: Alireza Rezania